Do analysts rate ABVC or PYXS?

Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 138.93%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63

Is ABVC or PYXS more profitable?

ABVC BioPharma's return on equity of -62.46% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Pyxis Oncology N/A -135.60% -85.00%

Does the media prefer ABVC or PYXS?

In the previous week, Pyxis Oncology had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Pyxis Oncology's score of 0.62 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ADCT or ABVC?

ADC Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 498.66%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ADC Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ADCT or ABVC?

In the previous week, ADC Therapeutics had 5 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for ADC Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat ADC Therapeutics' score of 0.24 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CNTB or ABVC?

Connect Biopharma currently has a consensus price target of $7.17, indicating a potential upside of 201.12%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Connect Biopharma is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CNTB or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Connect Biopharma N/A -122.29% -97.07% ABVC BioPharma N/A -62.46% -39.99%

Does the media refer more to CNTB or ABVC?

In the previous week, Connect Biopharma had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Connect Biopharma and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Connect Biopharma's score of 0.89 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend OGI or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organigram Global 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer MENS or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, MENS or ABVC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A ABVC BioPharma N/A N/A -$7.91M -$0.40 N/A

Is MENS or ABVC more profitable?

Jyong Biotech's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A ABVC BioPharma N/A -62.46% -39.99%

ABVC BioPharma (ABVC) Competitors

$1.57 +0.04 (+2.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.51 -0.06 (-3.82%)

As of 04:40 PM Eastern

Compare

ABVC vs. PYXS, ADCT, CNTB, OGI, and MENS

Should you buy ABVC BioPharma stock or one of its competitors? MarketBeat compares ABVC BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ABVC BioPharma include Pyxis Oncology (PYXS), ADC Therapeutics (ADCT), Connect Biopharma (CNTB), Organigram Global (OGI), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry.

How does ABVC BioPharma compare to Pyxis Oncology?

ABVC BioPharma (NASDAQ:ABVC) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 138.93%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Pyxis Oncology had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Pyxis Oncology's score of 0.62 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ABVC BioPharma has higher earnings, but lower revenue than Pyxis Oncology. ABVC BioPharma is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A
Pyxis Oncology	$13.86M	13.07	-$79.62M	-$1.31	N/A

ABVC BioPharma has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

ABVC BioPharma's return on equity of -62.46% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Pyxis Oncology	N/A	-135.60%	-85.00%

Summary

Pyxis Oncology beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ADC Therapeutics presently has a consensus price target of $6.25, indicating a potential upside of 498.66%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ADC Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
ABVC BioPharma	N/A	-62.46%	-39.99%

ABVC BioPharma has lower revenue, but higher earnings than ADC Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.63	-$142.62M	-$1.05	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A

In the previous week, ADC Therapeutics had 5 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for ADC Therapeutics and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat ADC Therapeutics' score of 0.24 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADC Therapeutics has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Summary

ADC Therapeutics beats ABVC BioPharma on 9 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

ABVC BioPharma's return on equity of -62.46% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
ABVC BioPharma	N/A	-62.46%	-39.99%

In the previous week, Connect Biopharma had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Connect Biopharma and 2 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.24 beat Connect Biopharma's score of 0.89 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Connect Biopharma currently has a consensus price target of $7.17, indicating a potential upside of 201.12%. Given Connect Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Connect Biopharma is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Connect Biopharma has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

ABVC BioPharma has lower revenue, but higher earnings than Connect Biopharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Connect Biopharma beats ABVC BioPharma on 9 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to Organigram Global?

Organigram Global (NASDAQ:OGI) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

ABVC BioPharma has lower revenue, but higher earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram Global	$274.19M	0.52	-$17.70M	-$0.13	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A

34.6% of Organigram Global shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 0.1% of Organigram Global shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Organigram Global has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, ABVC BioPharma had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 1.89 beat ABVC BioPharma's score of 1.24 indicating that Organigram Global is being referred to more favorably in the media.

Company	Overall Sentiment
Organigram Global	Very Positive
ABVC BioPharma	Positive

ABVC BioPharma has a net margin of 0.00% compared to Organigram Global's net margin of -9.22%. Organigram Global's return on equity of -13.41% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organigram Global	-9.22%	-13.41%	-9.09%
ABVC BioPharma	N/A	-62.46%	-39.99%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram Global	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Organigram Global beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, ABVC BioPharma had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat ABVC BioPharma's score of 1.24 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
ABVC BioPharma	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
ABVC BioPharma	N/A	N/A	-$7.91M	-$0.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
ABVC BioPharma	N/A	-62.46%	-39.99%

Summary

Jyong Biotech beats ABVC BioPharma on 4 of the 7 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.82M	$3.65B	$6.84B	$12.44B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-3.92	21.29	25.83	24.36
Price / Sales	N/A	313.32	541.54	96.87
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	3.02	8.71	10.98	6.49
Net Income	-$7.91M	$23.87M	$3.57B	$336.61M
7 Day Performance	18.94%	4.23%	3.06%	0.90%
1 Month Performance	11.35%	1.71%	0.72%	-0.36%
1 Year Performance	-39.38%	69.92%	36.82%	31.26%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.7086 of 5 stars	$1.57 +2.6%	N/A	-41.4%	$40.82M	N/A	N/A	30	Gap Up
PYXS Pyxis Oncology	2.6752 of 5 stars	$2.17 +3.3%	$6.83 +214.9%	+151.8%	$137.48M	$13.86M	N/A	60
ADCT ADC Therapeutics	3.3631 of 5 stars	$1.08 -6.5%	$6.25 +481.4%	-61.7%	$136.73M	$79.18M	N/A	310	Gap Up
CNTB Connect Biopharma	4.4858 of 5 stars	$2.12 +1.4%	$7.20 +239.6%	+120.5%	$133.48M	$233K	N/A	110	News Coverage Analyst Forecast Gap Up
OGI Organigram Global	0.8435 of 5 stars	$0.94 -0.7%	N/A	-23.7%	$133.00M	$185.07M	N/A	1,139	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. PYXS, ADCT, CNTB, OGI, and MENS

How does ABVC BioPharma compare to Pyxis Oncology?

Summary

How does ABVC BioPharma compare to ADC Therapeutics?

Summary

How does ABVC BioPharma compare to Connect Biopharma?

Summary

How does ABVC BioPharma compare to Organigram Global?

Summary

How does ABVC BioPharma compare to Jyong Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. PYXS, ADCT, CNTB, OGI, and MENS

How does ABVC BioPharma compare to Pyxis Oncology?

Do analysts rate ABVC or PYXS?

Do insiders & institutionals hold more shares of ABVC or PYXS?

Does the media prefer ABVC or PYXS?

Which has better earnings and valuation, ABVC or PYXS?

Which has more volatility & risk, ABVC or PYXS?

Is ABVC or PYXS more profitable?

Summary

How does ABVC BioPharma compare to ADC Therapeutics?

Do insiders and institutionals have more ownership in ADCT or ABVC?

Do analysts rate ADCT or ABVC?

Is ADCT or ABVC more profitable?

Which has higher valuation and earnings, ADCT or ABVC?

Does the media favor ADCT or ABVC?

Which has more risk & volatility, ADCT or ABVC?

Summary

How does ABVC BioPharma compare to Connect Biopharma?

Is CNTB or ABVC more profitable?

Does the media refer more to CNTB or ABVC?

Do analysts rate CNTB or ABVC?

Which has more volatility & risk, CNTB or ABVC?

Which has preferable valuation and earnings, CNTB or ABVC?

Do insiders and institutionals believe in CNTB or ABVC?

Summary

How does ABVC BioPharma compare to Organigram Global?

Which has stronger valuation & earnings, OGI or ABVC?

Do insiders & institutionals believe in OGI or ABVC?

Which has more risk and volatility, OGI or ABVC?

Does the media favor OGI or ABVC?

Is OGI or ABVC more profitable?

Do analysts recommend OGI or ABVC?

Summary

How does ABVC BioPharma compare to Jyong Biotech?

Do insiders and institutionals hold more shares of MENS or ABVC?

Does the media prefer MENS or ABVC?

Which has preferable earnings and valuation, MENS or ABVC?

Do analysts prefer MENS or ABVC?

Is MENS or ABVC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools